Sunday 18 October 2026
Export ENTA’s income statement to Excel — free account
Enanta Pharmaceuticals, Inc.
ENTA Healthcare Biotechnology
Enanta Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended September 2025) was $65.3 million, down 3.42% from fiscal 2024. In the quarter to June 2026, revenue fell 21.6%, EPS grew 21.2% and free cash flow fell 157.5%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
11.10
0.37
−3.23%
Follow ENTA
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
4 | 4 | 4 | 4 |
+8 more TTM periods Free account |
| (70.12%) | (59.00%) | (60.01%) | (84.63%) | ||
| (21.15%) | (19.44%) | (21.10%) | (24.91%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(34.86%) | (37.55%) | (38.00%) | (42.83%) | |
Average Days of Receivables |
36.55 | 41.28 | 46.28 | 38.45 | |
Free Cash Flow per Share |
(1.27) | (0.33) | (0.64) | (1.51) | |
Free Cash Flow |
(36.94) | (9.61) | (18.46) | (32.17) | |
Capital Expenditures |
(1.62) | (1.77) | (4.29) | (12.90) | |
| Other line items | |||||
Cash ROIC |
(12.71%) | (3.43%) | (5.91%) | (12.69%) | |
Accounts Receivable Turnover |
8.76 | 2.86 | 2.75 | 2.87 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | (0.02) | (0.02) | |
Research and Development Expense of Revenue |
132.15% | 131.94% | 149.21% | 163.40% | |
Selling, General and Administrative Expense of Revenue |
57.84% | 55.30% | 59.86% | 67.25% | |
Share Based Compensation of Revenue |
23.41% | 22.78% | 24.95% | 28.42% | |
Interest Coverage |
(4.55) | (5.80) | (8.30) | (11.11) | |
Operating CF/Net income |
0.56 | 0.13 | 0.20 | 0.24 | |
Depreciation/Fixed assets |
0.13 | 0.13 | 0.14 | 0.14 | |
Capex/Depreciation |
(0.38) | (0.41) | (0.89) | (2.53) | |
Revenue per Share |
2.24 | 2.38 | 2.33 | 3.06 | |
Operating CF per Share |
(1.21) | (0.27) | (0.49) | (0.90) | |
Capex per Share |
(0.06) | (0.06) | (0.15) | (0.60) | |
Capex to Sales |
0.02 | 0.03 | 0.06 | 0.20 |
Columns are period end dates